Business Context and Reporting Period
Company: United States Antimony Corporation (UAMY)
Filing Type: Form 8-K (Current Report)
Date of Report: October 10, 2025
Principal Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock.
Key Financial Metrics
| Metric | Value |
|---|---|
| Shares Issued | 2,377,657 |
| Price Per Share | $10.50 |
| Gross Proceeds | Approximately $25,000,000 |
| Net Proceeds (after expenses/credit) | $24,431,090.53 |
| Placement Agent Commission | 7% of gross proceeds (less credit) |
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
- Capital Structure: The Company agreed to sell 2,377,657 shares of Common Stock to an institutional investor, increasing outstanding share count upon closing.
- Liquidity: The transaction is expected to generate approximately $25 million in gross proceeds, significantly boosting cash reserves pending closing.
- ATM Facility Status: The Company's At-The-Market (ATM) offering capacity was reduced from $65,000,000 to $39,885,000 on October 6, 2025. As of October 10, 2025, no further sales can be made under the current ATM Prospectus Supplement due to this offering.
Outlook, Risks, and Management Commentary
- Closing Date: The Offering is expected to close on or about October 14, 2025, subject to customary closing conditions.
- Future Offerings: The Company cannot make further sales under the existing sales agreement until a new prospectus supplement and registration statement are filed.
- Placement Agent: Titan Partners Group LLC (a division of American Capital Partners, LLC) acted as the exclusive placement agent.
- Risks: The filing notes that the transaction is subject to satisfaction of customary closing conditions. No specific operational risks or contingencies regarding the Company's core antimony business are detailed in this specific 8-K.
Investor Verification Checklist
- Verify the final closing date and confirmation of net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor the filing of a new prospectus supplement required to reactivate the ATM facility.
- Confirm the identity of the institutional investor if disclosed in subsequent filings.
- Check for any dilution impact on earnings per share in the next quarterly report.